title: Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
abstract: In recent years, several nonhormonal and hormonal agents, including enzalutamide, have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on the basis of improved overall survival in prospective clinical trials. The incorporation of these agents has revolutionized the treatment of CRPC but has also raised the question of what is the ideal sequence of administering them. Enzalutamide is a nonsteroidal second-generation antiandrogen that has been approved for the treatment of metastatic CRPC both in the post-docetaxel and chemotherapy-naïve settings. This article reviews the pharmacological characteristics of enzalutamide, the efficacy studies which led to its approval, its safety profile, and quality of life-related parameters as well as its place in the sequential treatment and management of metastatic prostate cancer.
authors.affiliation: Medical Oncology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
authors.forename: Alejo
authors.initials: A
authors.lastname: Rodriguez-Vida
authors.affiliation: Medical Oncology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
authors.forename: Myria
authors.initials: M
authors.lastname: Galazi
authors.affiliation: Medical Oncology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
authors.forename: Sarah
authors.initials: S
authors.lastname: Rudman
authors.affiliation: Medical Oncology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
authors.forename: Simon
authors.initials: S
authors.lastname: Chowdhury
authors.affiliation: Medical Oncology Department, San Camillo and Forlanini Hospitals, Rome, Italy.
authors.forename: Cora N
authors.initials: CN
authors.lastname: Sternberg
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide
keywords: ADT; androgen receptor; antiandrogen; castration resistant prostate cancer; enzalutamide; overall survival